# Oruka Therapeutics, Inc.: financial statements, quarterly

ORKA · Nasdaq · CIK 907654 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/orka.md) · [Financials](/companies/orka/financials.md) · [Filings](/companies/orka/filings.md) · [Insiders](/companies/orka/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/orka/financials.md?period=annual).

## Income statement

| Line item | Unit | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2025 (2024-03-31) | Q2 FY2025 (2024-06-30) | Q3 FY2025 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [0.0 d](/filings/0000950170-23-033834.md) | [0.0 d](/filings/0000950170-23-053972.md) | [0.0 d](/filings/0000950170-24-009809.md) | [0.0](/filings/0000950170-24-048329.md) | [0.0 d](/filings/0000950170-24-089246.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $m | [0.3](/filings/0000950170-24-089246.md) | [0.3](/filings/0000950170-23-053972.md) | [0.0 d](/filings/0000950170-24-009809.md) | [0.2](/filings/0000950170-24-048329.md) | [18.7](/filings/0001213900-25-074281.md) | [25.7](/filings/0001213900-25-109182.md) | [19.9](/filings/0001213900-26-055769.md) | [24.1](/filings/0001213900-26-087231.md) | [29.0](/filings/0001213900-25-109182.md) | [27.6 d](/filings/0001213900-26-026929.md) | [29.1](/filings/0001213900-26-055769.md) | [43.3](/filings/0001213900-26-087231.md) |
| Selling, general and administrative | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating income | $m | [(2.0)](/filings/0000950170-24-089246.md) | [(1.9)](/filings/0000950170-23-053972.md) | [(1.6) d](/filings/0000950170-24-009809.md) | [(2.5)](/filings/0000950170-24-048329.md) | [(21.5)](/filings/0001213900-25-074281.md) | [(29.4)](/filings/0001213900-25-109182.md) | [(25.1)](/filings/0001213900-26-055769.md) | [(28.4)](/filings/0001213900-26-087231.md) | [(34.1)](/filings/0001213900-25-109182.md) | [(34.4) d](/filings/0001213900-26-026929.md) | [(36.4)](/filings/0001213900-26-055769.md) | [(50.1)](/filings/0001213900-26-087231.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | [0.8](/filings/0001213900-25-074281.md) | [0.5](/filings/0001213900-25-109182.md) | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net income | $m | [(1.5)](/filings/0000950170-24-089246.md) | [(1.4)](/filings/0000950170-24-089246.md) | [(1.1)](/filings/0000950170-24-089246.md) | [(2.0)](/filings/0000950170-24-089246.md) | [(22.2)](/filings/0001213900-25-074281.md) | [(28.6)](/filings/0001213900-25-109182.md) | [(21.0)](/filings/0001213900-26-087231.md) | [(24.6)](/filings/0001213900-26-087231.md) | [(30.3)](/filings/0001213900-25-109182.md) | [(29.6) d](/filings/0001213900-26-026929.md) | [(31.8)](/filings/0001213900-26-087231.md) | [(41.2)](/filings/0001213900-26-087231.md) |
| Diluted EPS | $ per share | [(0.10)](/filings/0000950170-24-089246.md) | [(0.10)](/filings/0000950170-23-053972.md) | not reported | [(0.14)](/filings/0000950170-24-048329.md) | [(6.96)](/filings/0001213900-25-074281.md) | [(1.46)](/filings/0001213900-24-097443.md) | [(0.40)](/filings/0001213900-25-043279.md) | [(0.46)](/filings/0001213900-25-074281.md) | not reported | not reported | not reported | not reported |
| Basic EPS | $ per share | [(0.10)](/filings/0000950170-24-089246.md) | [(0.10)](/filings/0000950170-23-053972.md) | not reported | [(0.14)](/filings/0000950170-24-048329.md) | [(6.96)](/filings/0001213900-25-074281.md) | [(1.46)](/filings/0001213900-24-097443.md) | [(0.40)](/filings/0001213900-25-043279.md) | [(0.46)](/filings/0001213900-25-074281.md) | not reported | not reported | not reported | not reported |

- Revenue: us-gaap:Revenues
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: not reported
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpenseNonoperating
- Income tax: not reported
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | FY2023 (2023-12-31) | period not labelled (2024-02-06) | Q1 FY2025 (2024-03-31) | Q2 FY2025 (2024-06-30) | Q3 FY2025 (2024-09-30) | FY2025 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [37.4](/filings/0000950170-24-089246.md) | not reported | [35.9](/filings/0000950170-24-048329.md) | [33.3](/filings/0000950170-24-089246.md) | [411](/filings/0001213900-24-097443.md) | [61.6](/filings/0001213900-26-026929.md) | [83.6](/filings/0001213900-25-043279.md) | [65.4](/filings/0001213900-25-074281.md) | [91.3](/filings/0001213900-25-109182.md) | [46.9](/filings/0001213900-26-087231.md) | [49.5](/filings/0001213900-26-055769.md) | [268](/filings/0001213900-26-087231.md) |
| Current assets | $m | [37.6](/filings/0000950170-24-089246.md) | [0.0](/filings/0001213900-25-021165.md) | [36.7](/filings/0000950170-24-048329.md) | [33.8](/filings/0000950170-24-089246.md) | [413](/filings/0001213900-24-097443.md) | [377](/filings/0001213900-26-026929.md) | [352](/filings/0001213900-25-043279.md) | [332](/filings/0001213900-25-074281.md) | [355](/filings/0001213900-25-109182.md) | [344](/filings/0001213900-26-087231.md) | [395](/filings/0001213900-26-055769.md) | [885](/filings/0001213900-26-087231.md) |
| Total assets | $m | [37.9](/filings/0000950170-24-089246.md) | [0.0](/filings/0001213900-25-021165.md) | [36.7](/filings/0000950170-24-048329.md) | [33.8](/filings/0000950170-24-089246.md) | [414](/filings/0001213900-24-097443.md) | [396](/filings/0001213900-26-026929.md) | [377](/filings/0001213900-25-043279.md) | [357](/filings/0001213900-25-074281.md) | [509](/filings/0001213900-25-109182.md) | [489](/filings/0001213900-26-087231.md) | [504](/filings/0001213900-26-055769.md) | [1,139](/filings/0001213900-26-087231.md) |
| Current liabilities | $m | [0.6](/filings/0000950170-24-089246.md) | not reported | [1.6](/filings/0000950170-24-048329.md) | [1.3](/filings/0000950170-24-089246.md) | [18.0](/filings/0001213900-24-097443.md) | [13.0](/filings/0001213900-26-026929.md) | [11.7](/filings/0001213900-25-043279.md) | [12.1](/filings/0001213900-25-074281.md) | [21.0](/filings/0001213900-25-109182.md) | [15.4](/filings/0001213900-26-087231.md) | [16.6](/filings/0001213900-26-055769.md) | [23.0](/filings/0001213900-26-087231.md) |
| Total liabilities | $m | [0.8](/filings/0000950170-24-089246.md) | not reported | [1.6](/filings/0000950170-24-048329.md) | [1.3](/filings/0000950170-24-089246.md) | [18.9](/filings/0001213900-24-097443.md) | [13.8](/filings/0001213900-26-026929.md) | [12.4](/filings/0001213900-25-043279.md) | [13.8](/filings/0001213900-25-074281.md) | [22.5](/filings/0001213900-25-109182.md) | [16.7](/filings/0001213900-26-087231.md) | [17.8](/filings/0001213900-26-055769.md) | [24.8](/filings/0001213900-26-087231.md) |
| Shareholders' equity | $m | [37.0](/filings/0000950170-24-089246.md) | [0.0](/filings/0001213900-25-043279.md) | [(7.1)](/filings/0001213900-25-109182.md) | [(29.0)](/filings/0001213900-25-109182.md) | [342](/filings/0001213900-25-109182.md) | [382](/filings/0001213900-26-087231.md) | [365](/filings/0001213900-26-087231.md) | [344](/filings/0001213900-26-087231.md) | [487](/filings/0001213900-25-109182.md) | [472](/filings/0001213900-26-087231.md) | [487](/filings/0001213900-26-087231.md) | [1,115](/filings/0001213900-26-087231.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2025 (2024-03-31) | Q2 FY2025 (2024-06-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(1.6)](/filings/0000950170-24-048329.md) | [(0.7) d](/filings/0000950170-24-089246.md) | [(1.7) d](/filings/0000950170-23-053972.md) | [(1.1) d](/filings/0000950170-24-009809.md) | [(1.5)](/filings/0000950170-24-048329.md) | [(2.6) d](/filings/0000950170-24-089246.md) | [(20.9)](/filings/0001213900-26-055769.md) | [(23.1) d](/filings/0001213900-26-087231.md) | [(21.6) d](/filings/0001213900-25-109182.md) | [(22.6) d](/filings/0001213900-26-026929.md) | [(23.6)](/filings/0001213900-26-055769.md) | [(33.1) d](/filings/0001213900-26-087231.md) |
| Capital expenditure | $m | not reported | not reported | not reported | not reported | not reported | not reported | [0.0](/filings/0001213900-26-055769.md) | [0.0 d](/filings/0001213900-26-087231.md) | [0.1 d](/filings/0001213900-25-109182.md) | [0.1 d](/filings/0001213900-26-026929.md) | [0.1](/filings/0001213900-26-055769.md) | [0.0 d](/filings/0001213900-26-087231.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2021 (2021-09-30) | Q1 FY2022 (2022-03-31) | Q2 FY2022 (2022-06-30) | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q1 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2025 (2024-03-31) | Q2 FY2025 (2024-06-30) | Q3 FY2025 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [14.4](/filings/0001564590-22-035668.md) | [14.4](/filings/0000950170-23-014091.md) | [14.4](/filings/0000950170-23-033834.md) | [14.4](/filings/0000950170-23-053972.md) | [14.4](/filings/0000950170-24-048329.md) | [14.4](/filings/0000950170-24-089246.md) | [14.4](/filings/0000950170-23-053972.md) | [14.5](/filings/0000950170-24-048329.md) | [3.2](/filings/0001213900-25-074281.md) | [15.0](/filings/0001213900-24-097443.md) | [41.7](/filings/0001213900-25-043279.md) | [42.1](/filings/0001213900-25-074281.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 66,209,699 at 2026-07-31, from the cover of the [10-Q filed 2026-08-10](/filings/0001213900-26-087231.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:28 ET. No prices; not investment advice.